The application of regorafenib and sorafenib indicates the full opening of the second-line treatment of HCC, and more effective new drugs and the most influential immune checkpoint inhibitors (ICIs) have emerged, which have made a great contribution to prolonging the survival of patients with HCC.[28] Regulatory T cells (Tregs) is a subgroup of CD4 + T cells, which plays an indispensable role in immune tolerance.[29] Tregs also play a very important role in the TME. Here, CD4 is linked to hepatocellular carcinoma.